What is the appropriate diagnostic work‑up and management for a patient with concentric left ventricular hypertrophy (LVH) and moderate pulmonary hypertension (PH)?

Management of Concentric LVH with Moderate Pulmonary Hypertension

The primary goal is to aggressively treat the underlying left heart disease causing the pulmonary hypertension, focusing on optimizing volume status with diuretics, initiating SGLT2 inhibitors for disease modification, and controlling blood pressure—while strictly avoiding pulmonary arterial hypertension-specific therapies that can cause harm in this population. 1, 2

Confirm the Diagnosis: This is PH-LHD (Group 2 PH)

The clinical presentation of concentric LVH with moderate pulmonary hypertension strongly suggests pulmonary hypertension secondary to left heart disease (PH-LHD), not pulmonary arterial hypertension. 1

Key diagnostic features supporting PH-LHD include:

• Concentric LV hypertrophy and/or increased LV mass on echocardiography 1
• ECG findings of LVH and/or left atrial hypertrophy 1
• Doppler indices of increased filling pressures (elevated E/e' ratio) 1
• Left atrial enlargement (>4.2 cm) 1
• Age >65 years, features of metabolic syndrome, or history of hypertension 1

Right heart catheterization is indicated to confirm the diagnosis and distinguish between isolated post-capillary PH (Ipc-PH) versus combined post- and pre-capillary PH (Cpc-PH), measuring pulmonary capillary wedge pressure (PCWP >15 mmHg confirms post-capillary PH), diastolic pressure gradient (DPG), and pulmonary vascular resistance (PVR). 1, 2, 3

Immediate Treatment Strategy

1. Aggressive Diuresis to Reduce LV Filling Pressures

Start loop diuretics immediately to reduce left ventricular filling pressures and pulmonary venous congestion. 2, 4

• Initiate furosemide 40-80 mg IV daily (or equivalent bumetanide/torsemide) 2
• Titrate to the lowest effective dose that relieves congestion without causing hypotension or worsening renal function 2
• If inadequate response, add thiazide diuretic (metolazone 2.5-5 mg daily) for sequential nephron blockade 2
• Monitor daily weights, fluid input/output, and electrolytes (especially potassium) 4
• Assess renal function regularly to avoid pre-renal failure from excessive volume depletion 4

2. Initiate SGLT2 Inhibitor (Disease-Modifying Therapy)

Start dapagliflozin 10 mg daily or empagliflozin 10 mg daily as first-line disease-modifying therapy for heart failure with preserved ejection fraction (HFpEF), which is the typical phenotype with concentric LVH. 2

• DELIVER trial: dapagliflozin reduced worsening HF and cardiovascular death (HR 0.82,95% CI 0.73-0.92) 2
• EMPEROR-PRESERVED trial: empagliflozin reduced HF hospitalization and CV death (HR 0.79,95% CI 0.69-0.90) 2

3. Blood Pressure Control and Afterload Reduction

Optimize blood pressure control targeting <130/80 mmHg using ACE inhibitors or ARBs to reduce afterload and prevent/reverse LV hypertrophy. 2, 3

• Start ACE inhibitor (lisinopril 10-40 mg daily) or ARB if ACE inhibitor intolerant (losartan 50-100 mg daily) 2
• These agents reduce LV filling pressures and promote regression of LV hypertrophy 3

4. Consider Mineralocorticoid Receptor Antagonist

Add spironolactone 12.5-25 mg daily, particularly given the moderate-to-severe pulmonary hypertension. 2

• TOPCAT trial: spironolactone reduced HF hospitalizations (HR 0.83,95% CI 0.69-0.99) 2
• Monitor potassium and renal function closely, especially when combined with ACE inhibitor/ARB 4

Critical Medications to AVOID

Absolutely avoid pulmonary arterial hypertension-specific therapies (prostanoids, endothelin receptor antagonists, PDE-5 inhibitors) in patients with PH-LHD, as these can cause pulmonary edema and clinical deterioration. 1, 2, 3

Avoid nondihydropyridine calcium channel blockers (diltiazem, verapamil) due to their negative inotropic effects that worsen heart failure. 2

Identify and Treat Contributing Conditions

Screen for and aggressively manage common comorbidities that worsen PH-LHD: 1, 2

• Sleep apnea syndrome (consider polysomnography if suspected)
• COPD (optimize bronchodilator therapy)
• Metabolic syndrome components (diabetes, obesity, dyslipidemia)
• Atrial fibrillation (rate/rhythm control, anticoagulation)

Monitoring and Follow-Up

Reassess volume status, symptoms, and functional capacity every 2-4 weeks initially during medication titration. 2

Repeat echocardiography in 3-6 months to assess response, specifically evaluating: 2

• LV mass regression
• RV function
• Estimated PA pressures
• Left atrial size

Advanced Therapy Considerations

If the patient remains severely symptomatic despite maximal medical therapy, refer to an advanced heart failure center for consideration of: 1, 2

• Left ventricular assist device (LVAD), which has been shown to lower pulmonary pressures through LV unloading 1, 2
• Heart transplantation evaluation 1, 2

Common Pitfalls to Avoid

The most critical error is misdiagnosing PH-LHD as pulmonary arterial hypertension, leading to inappropriate PAH-specific therapy that causes harm (pulmonary edema, hemodynamic deterioration). 3 Always systematically evaluate for left heart disease risk factors and carefully assess echocardiographic features of LV dysfunction, concentric hypertrophy, and left atrial enlargement before considering PAH therapies. 3

Assessing hemodynamics before optimizing volume status can lead to incorrect diagnosis—always optimize diuretic therapy before invasive assessment. 3

Underestimating the importance of right ventricular function: Up to 1 in 4 patients have a mismatch between right- and left-sided filling pressures, and disproportionate elevation of right-sided pressures (particularly with tricuspid regurgitation) hinders effective decongestion. 5